Characterisation of T cells induced by candidate conserved region HIV-1 vaccines in healthy HIV-1/2 negative volunteers
<p>HIV-1 has claimed the lives of millions of people globally and continues to spread despite development of highly active antiretroviral therapy. In 2013, 2.1 million new infections occurred and over 35 million people were living with HIV-1 infection. A prophylactic HIV-1 vaccine that can pre...
Váldodahkkit: | Ahmed, T, Tina Ahmed |
---|---|
Eará dahkkit: | Hanke, T |
Materiálatiipa: | Oahppočájánas |
Giella: | English |
Almmustuhtton: |
2014
|
Fáttát: |
Geahča maid
-
The design and development of an HIV-1 vaccine to elicit a broadly neutralising antibody response
Dahkki: Wan, L, et al.
Almmustuhtton: (2012) -
Architecture of the HIV-1 glycan shield
Dahkki: Pritchard, L
Almmustuhtton: (2014) -
HIV-specific interleukin-10 responses and immune modulation
Dahkki: Clutton, G
Almmustuhtton: (2012) -
Antibody-based HIV-1 vaccines: recent developments and future directions
Dahkki: Montefiori, D, et al.
Almmustuhtton: (2007) -
T-cell receptor (TCR) usage in HIV-2 infection
Dahkki: Moysi, E
Almmustuhtton: (2012)